Change in Serum Lactate Dehydrogenase Is Associated with
Outcome of Patients with Advanced-stage NSCLC Treated with
Erlotinib

J 2016

Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Ondrej TOPOLCAN; Jaroslav RACEK et al.

Základní údaje

Originální název

Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib

Autoři

Vydání

Anticancer Research, Athens, International Institute of Anticancer Research, 2016, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.937

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00090554

Organizační jednotka

Lékařská fakulta

UT WoS

000375456200054

EID Scopus

2-s2.0-85019071935

Klíčová slova anglicky

Lactate dehydrogenase; LDH; lung cancer; NSCLC; EGFR-TKI; erlotinib; prediction; biomarker

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 11. 2016 15:13, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Background: Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. Patients and Methods: Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment. Results: The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001). Conclusion: LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC.

Citovat

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Ondrej TOPOLCAN; Jaroslav RACEK; Martin SVATON; Radek KUCERA; Marek MINARIK; Lucie BENESOVA; Zbyněk BORTLÍČEK; Renata CHLOUPKOVÁ; Alexandr POPRACH a Tomas BUCHLER. Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib. Anticancer Research. Athens: International Institute of Anticancer Research, 2016, roč. 36, č. 5, s. 2459-2465. ISSN 0250-7005.

@article{1351371,
   author = {Fiala, Ondrej and Pesek, Milos and Finek, Jindrich and Topolcan, Ondrej and Racek, Jaroslav and Svaton, Martin and Kucera, Radek and Minarik, Marek and Benesova, Lucie and Bortlíček, Zbyněk and Chloupková, Renata and Poprach, Alexandr and Buchler, Tomas},
   article_location = {Athens},
   article_number = {5},
   keywords = {Lactate dehydrogenase; LDH; lung cancer; NSCLC; EGFR-TKI; erlotinib; prediction; biomarker},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib},
   volume = {36},
   year = {2016}
}

TY  - JOUR
ID  - 1351371
AU  - Fiala, Ondrej - Pesek, Milos - Finek, Jindrich - Topolcan, Ondrej - Racek, Jaroslav - Svaton, Martin - Kucera, Radek - Minarik, Marek - Benesova, Lucie - Bortlíček, Zbyněk - Chloupková, Renata - Poprach, Alexandr - Buchler, Tomas
PY  - 2016
TI  - Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib
JF  - Anticancer Research
VL  - 36
IS  - 5
SP  - 2459-2465
EP  - 2459-2465
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - Lactate dehydrogenase
KW  - LDH
KW  - lung cancer
KW  - NSCLC
KW  - EGFR-TKI
KW  - erlotinib
KW  - prediction
KW  - biomarker
N2  - Background: Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. Patients and Methods: Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment. Results: The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001). Conclusion: LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC.
ER  -

FIALA, Ondrej; Milos PESEK; Jindrich FINEK; Ondrej TOPOLCAN; Jaroslav RACEK; Martin SVATON; Radek KUCERA; Marek MINARIK; Lucie BENESOVA; Zbyněk BORTLÍČEK; Renata CHLOUPKOVÁ; Alexandr POPRACH a Tomas BUCHLER. Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2016, roč.~36, č.~5, s.~2459-2465. ISSN~0250-7005.

Přehled o publikaci